Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Ovarian Neoplasms × CB-839 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Mesothelioma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 61 Carboplatin 57 pembrolizumab 30 Cyclophosphamide 29 Bevacizumab 25 Cisplatin 24 liposomal doxorubicin 23 Gemcitabine 19 Topotecan 17 fludarabine 15 Docetaxel 14 olaparib 13 Taxes 13 niraparib 12 Nivolumab 12 veliparib 11 Doxorubicin 11 Albumin-Bound Paclitaxel 9 fludarabine phosphate 8 Filgrastim 8 sargramostim 7 durvalumab 7 aldesleukin 7 Peripheral Blood Stem Cell Transplantation 7 Oxaliplatin 7 Fluorouracil 7 Melphalan 6 Magnetic Resonance Spectroscopy 6 Leucovorin 6 Fulvestrant 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03944902 2023-11-21

BRCA

University of Alabama at Birmingham

Phase 1 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡